SlideShare a Scribd company logo
1 of 90
Alexandre Naime Barbosa MD, PhD
Infectious Diseases Professor
Winter School on Tropical Diseases
Botucatu School of Medicine - UNESP
2017 - Botucatu - SP - Brazil
O material que se segue faz parte do projeto didático do
Prof. Dr. Alexandre Naime Barbosa
Objetivos
1. Ensino: Treinamento de Estudantes e Profissionais da Área de Saúde;
2. Extensão: Facilitar o Contato da População em Geral com Conceitos Científicos;
3. Científico: Fomentar a Discussão Científica e Compartilhar Material Didático.
Autoria e Cessão
1. Conteúdo: Os dados contidos estão referenciados, em respeito ao autor original;
2. Uso: Está permitido o uso do material, desde que citada a fonte;
3. Contato: fale com o autor e conheça o seu projeto didático em:
The following material is part of the educational project produced by
Prof. Dr. Alexandre Naime Barbosa
Objectives
1. Education: Training for Students & Health Professionals
2. Community: Provide and Translate Scientific Information to the Population;
3. Scientific: Encourage the Scientific Discussion and Share Teaching Materials.
Authorship and Assignment
1. Content: The following data are referenced in respect to the original author;
2. Use: It is allowed to use the material, if the source is mentioned;
3. Contact: Talk to Dr. Barbosa and keep in touch with his project in:
1. Arbovirus: Overview
2. Yellow Fever
3. Dengue
4. Chikungunya
5. Zika
6. Conclusions
So what is the world's deadliest animal?
Maybe a smaller animal…
Arbovirus: Arthropod Borne viruses
WHO definition: viruses that are
maintained in nature principally, or to an
important extent, through biological
transmission between susceptible
vertebrate host by hematophagous
arthropods; viruses multiply in tissues of
arthropods, and are passed on to new
vertebrates by bites of arthropods after a
period of extrinsic incubation period.
Cycle Type 1: Man-Arthropod-Man
Cycle Type 2: Animal-Arthropod-Man
Family Members
Bunyaviridae La Crosse, Oropouche, Rift Valley, Sandfly, Crimean-Congo
Flaviviridae
Yellow Fever, Dengue, Zika, Japanese Encephalitis,
Saint Louis Encephalitis, West Nile, Kyasanur Forest, Omsk
Togaviridae
Chikungunya, O’nyong-nyong, Ross River, Equine Encephalitis
(East, West, Venezuelan), Sindbis
Encephalitis Syndrome
Virus Genus Vector Distribution
EEE Alphavirus Mosq. USA, Canada
WEE Alphavirus Mosq. USA, W. Indies
J.E Flavivirus Mosq. Orient
St. L.E Flavivirus Mosq. USA, C. America
La Crosse Bunyavirus Mosq. USA
Fever, with or without rash and arthralgia
Virus Genus Vector Distribution
Chickungunya Alphavirus Mosq. Africa, Asia, C&S Amer.
O’nyong-nyong Alphavirus Mosq. Africa
Sindbis Alphavirus Mosq. Africa, Asia, India
Dengue Flavivirus Mosq. Entire tropics, India
West Nile Flavivirus Mosq. Africa, India
Sandfly Phlebovirus Sandfly Med, Asia, India
Oropouche Bunyavirus Mosq. W.I, South America (N)
Hemorrhagic Fever
Virus Genus Vector Distribution
Chickungunya Alphavirus Mosq. Africa, Asia, C&S Amer.
Dengue Flavivirus Mosq. Entre tropics
Yellow Fever Flavivirus Mosq. Africa, S. America
Kyasanur Forest Disease Flavivirus Tick India(Karnataka)
Omsk HF Flavivirus Tick Russia
Crimean-Congo HF Nairovirus Tick Africa, Asia, E.U.
CDC - 2015
Family: Flaviviridae; Genus: Flavivirus
Distribution: restricted to Africa & Central and South America.
Brazil: Endemic vs Transition vs Free Areas
Brazil: Endemic vs Transition vs Free Areas
Casos Autóctones confirmados em 2017 no Brasil
Casos Autóctones confirmados em 2017 no Brasil
São Paulo State: Endemic vs Transition vs Free Areas
Casos Autóctones confirmados em 2017 em São Paulo
Botucatu 2009 Epidemic
Transmission:
Symptoms
The majority of persons infected with yellow
fever virus have no illness or only mild
illness.
In persons who develop symptoms, the
incubation period (time from infection until
illness) is typically 3–6 days.
The initial symptoms include sudden onset
of fever, chills, severe headache, back pain,
general body aches, nausea, and vomiting,
fatigue, and weakness. Most persons
improve after the initial presentation.
Symptoms
After a brief remission of hours to a day,
roughly 15% of cases progress to develop a
more severe form of the disease. The severe
form is characterized by high fever, jaundice,
bleeding, and eventually shock and failure of
multiple organs. Rate of Death: 50%
Pathogenesis
Diagnosis
Virus isolation
– From the blood or post-mortem liver tissue
Rapid diagnostic test:
– Detection viral genome by PCR in blood o tissues
– Not widely available
Detection IgM antibodies (ELISA)
– Simple sample provides a presumptive
diagnosis. Confirmation is made by a rise
between paired acute and convalescent samples
or a fall between early and late convalescent
samples.
– Cross-reactions with other flaviviruses
complicate the diagnosis particularity in Africa
(multiple flaviviruses cocirculate).
Treatment
No specific treatments have been
found to benefit patients with yellow
fever. Whenever possible, yellow
fever patients should be hospitalized
for supportive care and close
observation.
Treatment is symptomatic. Rest,
fluids, and use of pain relievers and
medication to reduce fever may
relieve symptoms of aching and
fever.
Prevention
Vaccine:
- Types: Inactivated mouse brain or Live attenuated
- Mandatory for people that live at endemic area and
travelers
Others
- Use insect repellent
- Wear proper clothing to reduce mosquito bites
- Be aware of peak mosquito hours
Family: Flaviviridae; Genus: Flavivirus, 4 Serotypes (1,2,3,4)
Distribution: all tropical and some subtropical areas
- WHO: 2.5 billion people, two fifths
of the world's population, at risk from
dengue and estimates that there may
be 50 million cases of dengue
infection worldwide every year. The
disease is endemic in more than 100
countries
Brazil: 2014 - 2015 - 2016 - 2017 Epidemic
2016: 1.180.472
2015: 745.957
Transmission: 1 patterns (Cycle)
1. Person to person transmission by Aedes
A. aegypti (America) and A. albopictus (Asia)
Classic Dengue (Break bone Fever)
- Incubation: 3-10 days;
- Chills, high fever, intense headache, myalgia,
arthralgia, retro-orbital pain, colic pain and
abdominal tenderness. Fever biphasic (saddle
type).
- Maculopapular rashes develop on chest, trunk.
Dengue Hemorrhagic Fever (DHF) &
Dengue Shock Syndrome (DSS)
C/F-High fever, hemorrhagic phenomena
including bleeding from the eyes, nose, mouth,
ear, into the gut, and oozing of blood from skin
pores, thrombocytopenia, and
hemoconcentration
Vascular leak syndrome - blood leaks through
the skin and into spaces around the lungs and
abdomen. This fluid loss and severe bleeding can
cause blood pressure to fall; then Dengue Shock
Syndrome (DSS) sets in, which has a high
mortality rate.
Pathogenesis
Diagnosis
- Isolation of virus from blood
- Serology:
-Antibody detection IgM
-Antigen detection- NS1 ag
- RT-PCR
Treatment
No antiviral therapy available
Symptomatic management in majority of cases
Suitable fluid replacement
Prevention
Family: Togaviridae; Genus Alphavirus
Distribution:
Epidemia Atual
2016: 135.030
2017: 43.010
Transmission: 2 patterns (Cycles)
1. Person to person transmission by Aedes sp.
2. Monkey-monkey by arboreal mosq. A. aegypti (America) and
A. albopictus (Asia)
Symptoms
- Fever
- Severe arthritis
- Chills, headache, photophobia
- Nausea, abdominal pain
- Rashes and petechias
Clinical Findings
Diagnosis
- Isolation of virus from blood
- Serology: Antibody detection IgM/IgG
- RT-PCR
Treatment and Prevention
No antiviral therapy available
Symptomatic management in majority of cases
No available vaccine
Family: Flaviviridae; Genus: Flavivirus
Distribution:
14
- 1940 - 50: First evidences of human infections (Zika = Forest in Uganda)
- 1940 - 50: First evidencies of human infection (East Africa)
- 2007: Big epidemic in Yap Island and Micronesia (80% of total population)
- 2013: French Polynesia (neurologic complications, and others)
- 2015: Brazil and South America (Microcephaly)
Beginning of 2015:
- 21 cases of “Dengue-Like”: 8 RT-PCR ZKV Positives (Natal - RN)
First Identifield Cases:
- April 2015: Camaçari (BA)
- May 2015: Natal (RN)
- May 2015: Sumaré (SP)
Route Theory
- Va’a (Canoe) World Sprint Championships (RJ, Ago/2014)
- Ocean Pacific Countries: French Polynesia, New Caledonia, Cook Island, Easter Island
- Zika circulation starts in 2014
- Brazil Zika virus is close to Polynesia virus
2016: 170.535
2017: 7.911
- Família: Flaviviridae
- Gênero: Flavivirus
- Vírus RNA
- Arbovírus
- Duas linhagens
- Africana
- Asiática
CDC - 2016
Importância Epidemiológica: Transmissão Vetorial
- Aedes aegypti, Aedes africanus e outros Aedes
- Culex???
Transmission: 2 patterns (Cycles)
1. Person to person transmission by Aedes sp.
2. Monkey-monkey by arboreal mosq.
Aedes aegypti
Aedes africanus,
Aedes apicoargenteus
Aedes furcifer
Aedes luteocephalus
Aedes vitattus
Outras Vias de Menor Importância Epidemiológica
- Transplacentária e Perinatal
- Transfusional
- Sexual
- Saliva e Urina (???)
- Leite Materno (??????)
- Período de Incubação (Mosquitos): 10 dias
- Reservatórios de Importância: Humanos e Pequenos Primatas
- Infecção em Humanos:
Células Dendríticas
Linfonodos
Corrente Sanguínea
- Sintomas Clínicos: Leves a Moderados (Febre, Rash Cutâneo e Conjuntivite)
- Associação Possível e Provável com Malformações Fetais e Sde. de Guillain-Barré
- Associação Causal e Dano Neurológico Direto (e outros): em estudo e análise
- Microcefalia pode ocorrer, mas não se limita a esse achado (Z-TORCH)
- Podem ocorrer medidas normais de PC, mas com graves malformações de SNC
- Necrose tecidual => Redução massa cerebral => Microcefalia
- Lisencefalia, hidrocefalia, calcificações multifocais corticais e subcorticais
- Perda do tecido cortical, e presença de necrose e inflamação
- Lesões oftalmológicas: mácula e peri-mácula; nervo óptico
- Artrogripose: endurecimento da musculatura e as articulações
- Taxa de Transmissão Transplacentária: 2-5% (???)
- ZKV no feto: permanência e reativação por um longo período
- Momento de maior risco na gestação (???)
18/Nov/2015
10/Fev/2016
13/04/2016
Pacientes com quadro de exantema máculo-papular e DOIS dos seguintes sintomas:
- febre (<38,5º C) ou
- hiperemia conjuntival sem secreção ou
- prurido ou
- artralgia ou
- edema periarticular
Outros Achados: mialgia, cefaleia, edema de membros inferiores, dor retrorbital,
anorexia, vômitos, diarreia ou dor abdominal.
Manifestações neurológicas:
- Síndrome de Guillain Barré, ADEM: 4 a 20 dias após o início dos sintomas
Symptoms
About 1 in 5 people infected with Zika virus
become ill.
The most common symptoms of Zika are fever,
rash, joint pain, or red eyes. Other symptoms
include muscle pain, headache, pain behind
the eyes, and vomiting.
The illness is usually mild with symptoms
lasting for several days to a week.
Severe disease requiring hospitalization is
uncommon.
Deaths due to Zika are very rare.
Matsuda EM - 2016
Brasil, Ministério da Saúde - 2016
Treatment and Prevention
No antiviral therapy available
Symptomatic management in majority of cases
No available vaccine
Não há vacina
Eliminação dos criadouros dos mosquitos
Evitar locais com presença do mosquito, uso de telas
Repelentes
- < 6 meses: sem indicação
- 6 meses - 2 anos: IR3535
- 2 anos a 12 anos: DEET 10% (no máximo, aplicar 3x/dia) ou Icaridina;
> 12 anos ou gestantes: DEET > 10% ou Icaridina
Uso de inseticidas
Uso de cobertura de áreas expostas com roupa
Atualização de carteira vacinal
11/03/2016
Obrigado pela Atenção!
SAE de Infectologia HC UNESP Botucatu Faculdade de Medicina UNESP

More Related Content

What's hot

What's hot (20)

Ebola virus
Ebola virusEbola virus
Ebola virus
 
Hepatitis B and C - Approach and Management : Updates 2020
Hepatitis B and C - Approach and Management : Updates 2020Hepatitis B and C - Approach and Management : Updates 2020
Hepatitis B and C - Approach and Management : Updates 2020
 
EBOLA an update 2017 by DrT.V.Rao MD
EBOLA an update2017 by DrT.V.Rao MDEBOLA an update2017 by DrT.V.Rao MD
EBOLA an update 2017 by DrT.V.Rao MD
 
Hepatitis viruses
Hepatitis virusesHepatitis viruses
Hepatitis viruses
 
ebola-epidemiology
ebola-epidemiologyebola-epidemiology
ebola-epidemiology
 
Ebola virus disease
Ebola virus  diseaseEbola virus  disease
Ebola virus disease
 
Ebola virus disease/ Ebola outbreak
Ebola virus disease/ Ebola outbreakEbola virus disease/ Ebola outbreak
Ebola virus disease/ Ebola outbreak
 
01 26 16 zika
01 26 16 zika01 26 16 zika
01 26 16 zika
 
General aspects and definitions of hepatitis B
General aspects and definitions of hepatitis BGeneral aspects and definitions of hepatitis B
General aspects and definitions of hepatitis B
 
Hepatitis b virus (hbv) infection a silent epidemic
Hepatitis b virus (hbv) infection a silent epidemicHepatitis b virus (hbv) infection a silent epidemic
Hepatitis b virus (hbv) infection a silent epidemic
 
HEPATITIS B - AN OVERVIEW
HEPATITIS B - AN OVERVIEWHEPATITIS B - AN OVERVIEW
HEPATITIS B - AN OVERVIEW
 
Ebola
EbolaEbola
Ebola
 
HEPATITIS - VIRUS
HEPATITIS - VIRUSHEPATITIS - VIRUS
HEPATITIS - VIRUS
 
Lassa Fever
Lassa FeverLassa Fever
Lassa Fever
 
Ebola ppt
Ebola pptEbola ppt
Ebola ppt
 
Simple Educational Slides on Hepatitis B #hepatitiscantwait #worldhepatitisday
Simple Educational Slides on Hepatitis B #hepatitiscantwait #worldhepatitisdaySimple Educational Slides on Hepatitis B #hepatitiscantwait #worldhepatitisday
Simple Educational Slides on Hepatitis B #hepatitiscantwait #worldhepatitisday
 
Ebola virus November 2014- A final update?
Ebola virus November 2014- A final update?Ebola virus November 2014- A final update?
Ebola virus November 2014- A final update?
 
Ebola virus disease (EVD)
Ebola virus disease (EVD)Ebola virus disease (EVD)
Ebola virus disease (EVD)
 
Ebola ppt
Ebola pptEbola ppt
Ebola ppt
 
Ebola Virus Disease
Ebola Virus DiseaseEbola Virus Disease
Ebola Virus Disease
 

Similar to Arbovirus in Brazil - Chikungunya, Dengue, Yellow Fever, Zika 2017

Leconrabies 120309125912-phpapp01
Leconrabies 120309125912-phpapp01Leconrabies 120309125912-phpapp01
Leconrabies 120309125912-phpapp01
Shiva Kumar E
 

Similar to Arbovirus in Brazil - Chikungunya, Dengue, Yellow Fever, Zika 2017 (20)

Chikungunya, Dengue, Yellow Fever, Zika 2015
Chikungunya, Dengue, Yellow Fever, Zika 2015Chikungunya, Dengue, Yellow Fever, Zika 2015
Chikungunya, Dengue, Yellow Fever, Zika 2015
 
6. Dengue Fever
6. Dengue Fever6. Dengue Fever
6. Dengue Fever
 
Zika virus disease
Zika virus diseaseZika virus disease
Zika virus disease
 
Arbo viruses
Arbo virusesArbo viruses
Arbo viruses
 
Meningococcal meningitis (dr.yla)
Meningococcal meningitis (dr.yla)Meningococcal meningitis (dr.yla)
Meningococcal meningitis (dr.yla)
 
Approach to acute febrile illness in Tropical regions
Approach to acute febrile illness in Tropical regions Approach to acute febrile illness in Tropical regions
Approach to acute febrile illness in Tropical regions
 
Dengue
DengueDengue
Dengue
 
Dengue
DengueDengue
Dengue
 
Dengue fever pravin yerpude
Dengue fever pravin yerpudeDengue fever pravin yerpude
Dengue fever pravin yerpude
 
19629 lec 12 arboviruses medical virology
19629 lec 12 arboviruses medical virology19629 lec 12 arboviruses medical virology
19629 lec 12 arboviruses medical virology
 
Diagnosis and treatment of URTI
Diagnosis and treatment of URTI Diagnosis and treatment of URTI
Diagnosis and treatment of URTI
 
Leconrabies 120309125912-phpapp01
Leconrabies 120309125912-phpapp01Leconrabies 120309125912-phpapp01
Leconrabies 120309125912-phpapp01
 
dengue.pptx
dengue.pptxdengue.pptx
dengue.pptx
 
Dengue hemorrhagic fever
Dengue hemorrhagic feverDengue hemorrhagic fever
Dengue hemorrhagic fever
 
25221.ppt
25221.ppt25221.ppt
25221.ppt
 
25221 (1).ppt
25221 (1).ppt25221 (1).ppt
25221 (1).ppt
 
Meningitis
MeningitisMeningitis
Meningitis
 
Dengue Fever
Dengue FeverDengue Fever
Dengue Fever
 
Dengue Fever Power Point
Dengue Fever Power PointDengue Fever Power Point
Dengue Fever Power Point
 
rabies ppt
rabies pptrabies ppt
rabies ppt
 

More from Alexandre Naime Barbosa

More from Alexandre Naime Barbosa (20)

Novas Estratégias de PrEP e PEP PrEP Sob Demanda, Longa Duração e DoxiPEP
Novas Estratégias de PrEP e PEP  PrEP Sob Demanda, Longa Duração e DoxiPEPNovas Estratégias de PrEP e PEP  PrEP Sob Demanda, Longa Duração e DoxiPEP
Novas Estratégias de PrEP e PEP PrEP Sob Demanda, Longa Duração e DoxiPEP
 
Vacuna anti COVID-19 2023
Vacuna anti COVID-19 2023Vacuna anti COVID-19 2023
Vacuna anti COVID-19 2023
 
Covid-19 Leve Atualizacao do Manejo Clinico
Covid-19 Leve Atualizacao do Manejo ClinicoCovid-19 Leve Atualizacao do Manejo Clinico
Covid-19 Leve Atualizacao do Manejo Clinico
 
Monkeypox CMBT Nov 2022.pptx
Monkeypox CMBT Nov 2022.pptxMonkeypox CMBT Nov 2022.pptx
Monkeypox CMBT Nov 2022.pptx
 
Efetividade Vacinas Covid CNNEI 2022.pptx
Efetividade Vacinas Covid CNNEI 2022.pptxEfetividade Vacinas Covid CNNEI 2022.pptx
Efetividade Vacinas Covid CNNEI 2022.pptx
 
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptx
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptxDengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptx
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptx
 
Doencas Emergentes Pos Pandemia CFM 2022
Doencas Emergentes Pos Pandemia CFM 2022Doencas Emergentes Pos Pandemia CFM 2022
Doencas Emergentes Pos Pandemia CFM 2022
 
Desafios Divulgação Cientifica Pandemia.pptx
Desafios Divulgação Cientifica Pandemia.pptxDesafios Divulgação Cientifica Pandemia.pptx
Desafios Divulgação Cientifica Pandemia.pptx
 
SARS-COV-2 e Covid-19 Atualização do Manejo Clínico
SARS-COV-2 e Covid-19 Atualização do Manejo ClínicoSARS-COV-2 e Covid-19 Atualização do Manejo Clínico
SARS-COV-2 e Covid-19 Atualização do Manejo Clínico
 
Movimentos Anti-Vacina Brasil 2022.pptx
Movimentos Anti-Vacina Brasil 2022.pptxMovimentos Anti-Vacina Brasil 2022.pptx
Movimentos Anti-Vacina Brasil 2022.pptx
 
Diretriz Tratamento Covid SBI InfectoSul.pptx
Diretriz Tratamento Covid SBI InfectoSul.pptxDiretriz Tratamento Covid SBI InfectoSul.pptx
Diretriz Tratamento Covid SBI InfectoSul.pptx
 
Hepatite C - Situação atual do tratamento no contexto do Brasil
Hepatite C - Situação atual do tratamento no contexto do BrasilHepatite C - Situação atual do tratamento no contexto do Brasil
Hepatite C - Situação atual do tratamento no contexto do Brasil
 
Covid-19 Moderada/Grave Tratamento de Pacientes Hospitalizados
Covid-19 Moderada/Grave Tratamento de Pacientes HospitalizadosCovid-19 Moderada/Grave Tratamento de Pacientes Hospitalizados
Covid-19 Moderada/Grave Tratamento de Pacientes Hospitalizados
 
Uso Racional Antibioticos Idosos
Uso Racional Antibioticos IdososUso Racional Antibioticos Idosos
Uso Racional Antibioticos Idosos
 
Infeccao pelo HIV e Covid-19
Infeccao pelo HIV e Covid-19Infeccao pelo HIV e Covid-19
Infeccao pelo HIV e Covid-19
 
Dengue - Impacto Epidemiologico e Manejo Clinico
Dengue - Impacto Epidemiologico e Manejo ClinicoDengue - Impacto Epidemiologico e Manejo Clinico
Dengue - Impacto Epidemiologico e Manejo Clinico
 
Hepatite C - O que falta resolver?
Hepatite C - O que falta resolver?Hepatite C - O que falta resolver?
Hepatite C - O que falta resolver?
 
Novas Perspectivas no Manejo Covid 2022
Novas Perspectivas no Manejo Covid 2022Novas Perspectivas no Manejo Covid 2022
Novas Perspectivas no Manejo Covid 2022
 
Prevencao e Terapeutica da Covid-19 com Anticorpos Monoclonais
Prevencao e Terapeutica da Covid-19 com Anticorpos MonoclonaisPrevencao e Terapeutica da Covid-19 com Anticorpos Monoclonais
Prevencao e Terapeutica da Covid-19 com Anticorpos Monoclonais
 
Atualizacoes Aprendizados e Perspectivas Pandemia Covid
Atualizacoes Aprendizados e Perspectivas Pandemia CovidAtualizacoes Aprendizados e Perspectivas Pandemia Covid
Atualizacoes Aprendizados e Perspectivas Pandemia Covid
 

Recently uploaded

Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
palsonia139
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 

Recently uploaded (20)

ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failure
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
 
Bhimrad + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x...
Bhimrad + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x...Bhimrad + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x...
Bhimrad + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x...
 
Young & Hot ℂall Girls Salem 8250077686 WhatsApp Number Best Rates of Surat ℂ...
Young & Hot ℂall Girls Salem 8250077686 WhatsApp Number Best Rates of Surat ℂ...Young & Hot ℂall Girls Salem 8250077686 WhatsApp Number Best Rates of Surat ℂ...
Young & Hot ℂall Girls Salem 8250077686 WhatsApp Number Best Rates of Surat ℂ...
 
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENTJOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
 
Kamrej + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7...
Kamrej + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7...Kamrej + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7...
Kamrej + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7...
 
The Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - Subconscious
 
Bangalore whatsapp Number Just VIP Brookefield 100% Genuine at your Door Step
Bangalore whatsapp Number Just VIP Brookefield 100% Genuine at your Door StepBangalore whatsapp Number Just VIP Brookefield 100% Genuine at your Door Step
Bangalore whatsapp Number Just VIP Brookefield 100% Genuine at your Door Step
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifier
 
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas Hospital
 
^In Pietermaritzburg Hager Werken Embalming +27789155305 Compound Powder in ...
^In Pietermaritzburg  Hager Werken Embalming +27789155305 Compound Powder in ...^In Pietermaritzburg  Hager Werken Embalming +27789155305 Compound Powder in ...
^In Pietermaritzburg Hager Werken Embalming +27789155305 Compound Powder in ...
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
DR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in IndiaDR. Neha Mehta Best Psychologist.in India
DR. Neha Mehta Best Psychologist.in India
 
Tips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examTips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES exam
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Young & Hot Surat ℂall Girls Dindoli 8527049040 WhatsApp AnyTime Best Surat ℂ...
Young & Hot Surat ℂall Girls Dindoli 8527049040 WhatsApp AnyTime Best Surat ℂ...Young & Hot Surat ℂall Girls Dindoli 8527049040 WhatsApp AnyTime Best Surat ℂ...
Young & Hot Surat ℂall Girls Dindoli 8527049040 WhatsApp AnyTime Best Surat ℂ...
 
Sell 5cladba adbb JWH-018 5FADB in stock
Sell 5cladba adbb JWH-018 5FADB in stockSell 5cladba adbb JWH-018 5FADB in stock
Sell 5cladba adbb JWH-018 5FADB in stock
 

Arbovirus in Brazil - Chikungunya, Dengue, Yellow Fever, Zika 2017

  • 1. Alexandre Naime Barbosa MD, PhD Infectious Diseases Professor Winter School on Tropical Diseases Botucatu School of Medicine - UNESP 2017 - Botucatu - SP - Brazil
  • 2. O material que se segue faz parte do projeto didático do Prof. Dr. Alexandre Naime Barbosa Objetivos 1. Ensino: Treinamento de Estudantes e Profissionais da Área de Saúde; 2. Extensão: Facilitar o Contato da População em Geral com Conceitos Científicos; 3. Científico: Fomentar a Discussão Científica e Compartilhar Material Didático. Autoria e Cessão 1. Conteúdo: Os dados contidos estão referenciados, em respeito ao autor original; 2. Uso: Está permitido o uso do material, desde que citada a fonte; 3. Contato: fale com o autor e conheça o seu projeto didático em:
  • 3. The following material is part of the educational project produced by Prof. Dr. Alexandre Naime Barbosa Objectives 1. Education: Training for Students & Health Professionals 2. Community: Provide and Translate Scientific Information to the Population; 3. Scientific: Encourage the Scientific Discussion and Share Teaching Materials. Authorship and Assignment 1. Content: The following data are referenced in respect to the original author; 2. Use: It is allowed to use the material, if the source is mentioned; 3. Contact: Talk to Dr. Barbosa and keep in touch with his project in:
  • 4. 1. Arbovirus: Overview 2. Yellow Fever 3. Dengue 4. Chikungunya 5. Zika 6. Conclusions
  • 5.
  • 6. So what is the world's deadliest animal?
  • 7. Maybe a smaller animal…
  • 8. Arbovirus: Arthropod Borne viruses WHO definition: viruses that are maintained in nature principally, or to an important extent, through biological transmission between susceptible vertebrate host by hematophagous arthropods; viruses multiply in tissues of arthropods, and are passed on to new vertebrates by bites of arthropods after a period of extrinsic incubation period.
  • 9. Cycle Type 1: Man-Arthropod-Man
  • 10. Cycle Type 2: Animal-Arthropod-Man
  • 11. Family Members Bunyaviridae La Crosse, Oropouche, Rift Valley, Sandfly, Crimean-Congo Flaviviridae Yellow Fever, Dengue, Zika, Japanese Encephalitis, Saint Louis Encephalitis, West Nile, Kyasanur Forest, Omsk Togaviridae Chikungunya, O’nyong-nyong, Ross River, Equine Encephalitis (East, West, Venezuelan), Sindbis
  • 12. Encephalitis Syndrome Virus Genus Vector Distribution EEE Alphavirus Mosq. USA, Canada WEE Alphavirus Mosq. USA, W. Indies J.E Flavivirus Mosq. Orient St. L.E Flavivirus Mosq. USA, C. America La Crosse Bunyavirus Mosq. USA
  • 13. Fever, with or without rash and arthralgia Virus Genus Vector Distribution Chickungunya Alphavirus Mosq. Africa, Asia, C&S Amer. O’nyong-nyong Alphavirus Mosq. Africa Sindbis Alphavirus Mosq. Africa, Asia, India Dengue Flavivirus Mosq. Entire tropics, India West Nile Flavivirus Mosq. Africa, India Sandfly Phlebovirus Sandfly Med, Asia, India Oropouche Bunyavirus Mosq. W.I, South America (N)
  • 14. Hemorrhagic Fever Virus Genus Vector Distribution Chickungunya Alphavirus Mosq. Africa, Asia, C&S Amer. Dengue Flavivirus Mosq. Entre tropics Yellow Fever Flavivirus Mosq. Africa, S. America Kyasanur Forest Disease Flavivirus Tick India(Karnataka) Omsk HF Flavivirus Tick Russia Crimean-Congo HF Nairovirus Tick Africa, Asia, E.U.
  • 16.
  • 17. Family: Flaviviridae; Genus: Flavivirus Distribution: restricted to Africa & Central and South America.
  • 18. Brazil: Endemic vs Transition vs Free Areas
  • 19. Brazil: Endemic vs Transition vs Free Areas
  • 20. Casos Autóctones confirmados em 2017 no Brasil
  • 21. Casos Autóctones confirmados em 2017 no Brasil
  • 22. São Paulo State: Endemic vs Transition vs Free Areas
  • 23. Casos Autóctones confirmados em 2017 em São Paulo
  • 26. Symptoms The majority of persons infected with yellow fever virus have no illness or only mild illness. In persons who develop symptoms, the incubation period (time from infection until illness) is typically 3–6 days. The initial symptoms include sudden onset of fever, chills, severe headache, back pain, general body aches, nausea, and vomiting, fatigue, and weakness. Most persons improve after the initial presentation.
  • 27. Symptoms After a brief remission of hours to a day, roughly 15% of cases progress to develop a more severe form of the disease. The severe form is characterized by high fever, jaundice, bleeding, and eventually shock and failure of multiple organs. Rate of Death: 50%
  • 29. Diagnosis Virus isolation – From the blood or post-mortem liver tissue Rapid diagnostic test: – Detection viral genome by PCR in blood o tissues – Not widely available Detection IgM antibodies (ELISA) – Simple sample provides a presumptive diagnosis. Confirmation is made by a rise between paired acute and convalescent samples or a fall between early and late convalescent samples. – Cross-reactions with other flaviviruses complicate the diagnosis particularity in Africa (multiple flaviviruses cocirculate).
  • 30. Treatment No specific treatments have been found to benefit patients with yellow fever. Whenever possible, yellow fever patients should be hospitalized for supportive care and close observation. Treatment is symptomatic. Rest, fluids, and use of pain relievers and medication to reduce fever may relieve symptoms of aching and fever.
  • 31. Prevention Vaccine: - Types: Inactivated mouse brain or Live attenuated - Mandatory for people that live at endemic area and travelers Others - Use insect repellent - Wear proper clothing to reduce mosquito bites - Be aware of peak mosquito hours
  • 32.
  • 33.
  • 34.
  • 35. Family: Flaviviridae; Genus: Flavivirus, 4 Serotypes (1,2,3,4) Distribution: all tropical and some subtropical areas - WHO: 2.5 billion people, two fifths of the world's population, at risk from dengue and estimates that there may be 50 million cases of dengue infection worldwide every year. The disease is endemic in more than 100 countries
  • 36. Brazil: 2014 - 2015 - 2016 - 2017 Epidemic 2016: 1.180.472 2015: 745.957
  • 37. Transmission: 1 patterns (Cycle) 1. Person to person transmission by Aedes A. aegypti (America) and A. albopictus (Asia)
  • 38. Classic Dengue (Break bone Fever) - Incubation: 3-10 days; - Chills, high fever, intense headache, myalgia, arthralgia, retro-orbital pain, colic pain and abdominal tenderness. Fever biphasic (saddle type). - Maculopapular rashes develop on chest, trunk.
  • 39. Dengue Hemorrhagic Fever (DHF) & Dengue Shock Syndrome (DSS) C/F-High fever, hemorrhagic phenomena including bleeding from the eyes, nose, mouth, ear, into the gut, and oozing of blood from skin pores, thrombocytopenia, and hemoconcentration Vascular leak syndrome - blood leaks through the skin and into spaces around the lungs and abdomen. This fluid loss and severe bleeding can cause blood pressure to fall; then Dengue Shock Syndrome (DSS) sets in, which has a high mortality rate.
  • 41. Diagnosis - Isolation of virus from blood - Serology: -Antibody detection IgM -Antigen detection- NS1 ag - RT-PCR
  • 42. Treatment No antiviral therapy available Symptomatic management in majority of cases Suitable fluid replacement
  • 44.
  • 45. Family: Togaviridae; Genus Alphavirus Distribution:
  • 47. Transmission: 2 patterns (Cycles) 1. Person to person transmission by Aedes sp. 2. Monkey-monkey by arboreal mosq. A. aegypti (America) and A. albopictus (Asia)
  • 48. Symptoms - Fever - Severe arthritis - Chills, headache, photophobia - Nausea, abdominal pain - Rashes and petechias
  • 50. Diagnosis - Isolation of virus from blood - Serology: Antibody detection IgM/IgG - RT-PCR
  • 51. Treatment and Prevention No antiviral therapy available Symptomatic management in majority of cases No available vaccine
  • 52.
  • 53. Family: Flaviviridae; Genus: Flavivirus Distribution:
  • 54. 14
  • 55. - 1940 - 50: First evidences of human infections (Zika = Forest in Uganda)
  • 56. - 1940 - 50: First evidencies of human infection (East Africa) - 2007: Big epidemic in Yap Island and Micronesia (80% of total population) - 2013: French Polynesia (neurologic complications, and others) - 2015: Brazil and South America (Microcephaly)
  • 57. Beginning of 2015: - 21 cases of “Dengue-Like”: 8 RT-PCR ZKV Positives (Natal - RN)
  • 58. First Identifield Cases: - April 2015: Camaçari (BA) - May 2015: Natal (RN) - May 2015: Sumaré (SP) Route Theory - Va’a (Canoe) World Sprint Championships (RJ, Ago/2014) - Ocean Pacific Countries: French Polynesia, New Caledonia, Cook Island, Easter Island - Zika circulation starts in 2014 - Brazil Zika virus is close to Polynesia virus
  • 59.
  • 61.
  • 62. - Família: Flaviviridae - Gênero: Flavivirus - Vírus RNA - Arbovírus - Duas linhagens - Africana - Asiática CDC - 2016
  • 63. Importância Epidemiológica: Transmissão Vetorial - Aedes aegypti, Aedes africanus e outros Aedes - Culex???
  • 64. Transmission: 2 patterns (Cycles) 1. Person to person transmission by Aedes sp. 2. Monkey-monkey by arboreal mosq. Aedes aegypti Aedes africanus, Aedes apicoargenteus Aedes furcifer Aedes luteocephalus Aedes vitattus
  • 65. Outras Vias de Menor Importância Epidemiológica - Transplacentária e Perinatal - Transfusional - Sexual - Saliva e Urina (???) - Leite Materno (??????)
  • 66. - Período de Incubação (Mosquitos): 10 dias - Reservatórios de Importância: Humanos e Pequenos Primatas - Infecção em Humanos: Células Dendríticas Linfonodos Corrente Sanguínea - Sintomas Clínicos: Leves a Moderados (Febre, Rash Cutâneo e Conjuntivite) - Associação Possível e Provável com Malformações Fetais e Sde. de Guillain-Barré - Associação Causal e Dano Neurológico Direto (e outros): em estudo e análise
  • 67. - Microcefalia pode ocorrer, mas não se limita a esse achado (Z-TORCH) - Podem ocorrer medidas normais de PC, mas com graves malformações de SNC - Necrose tecidual => Redução massa cerebral => Microcefalia - Lisencefalia, hidrocefalia, calcificações multifocais corticais e subcorticais - Perda do tecido cortical, e presença de necrose e inflamação - Lesões oftalmológicas: mácula e peri-mácula; nervo óptico - Artrogripose: endurecimento da musculatura e as articulações - Taxa de Transmissão Transplacentária: 2-5% (???) - ZKV no feto: permanência e reativação por um longo período - Momento de maior risco na gestação (???)
  • 71.
  • 72.
  • 73. Pacientes com quadro de exantema máculo-papular e DOIS dos seguintes sintomas: - febre (<38,5º C) ou - hiperemia conjuntival sem secreção ou - prurido ou - artralgia ou - edema periarticular Outros Achados: mialgia, cefaleia, edema de membros inferiores, dor retrorbital, anorexia, vômitos, diarreia ou dor abdominal. Manifestações neurológicas: - Síndrome de Guillain Barré, ADEM: 4 a 20 dias após o início dos sintomas
  • 74. Symptoms About 1 in 5 people infected with Zika virus become ill. The most common symptoms of Zika are fever, rash, joint pain, or red eyes. Other symptoms include muscle pain, headache, pain behind the eyes, and vomiting. The illness is usually mild with symptoms lasting for several days to a week. Severe disease requiring hospitalization is uncommon. Deaths due to Zika are very rare.
  • 75. Matsuda EM - 2016
  • 76. Brasil, Ministério da Saúde - 2016
  • 77. Treatment and Prevention No antiviral therapy available Symptomatic management in majority of cases No available vaccine
  • 78.
  • 79. Não há vacina Eliminação dos criadouros dos mosquitos Evitar locais com presença do mosquito, uso de telas Repelentes - < 6 meses: sem indicação - 6 meses - 2 anos: IR3535 - 2 anos a 12 anos: DEET 10% (no máximo, aplicar 3x/dia) ou Icaridina; > 12 anos ou gestantes: DEET > 10% ou Icaridina Uso de inseticidas Uso de cobertura de áreas expostas com roupa Atualização de carteira vacinal
  • 80.
  • 81.
  • 82.
  • 83.
  • 84.
  • 85.
  • 87.
  • 88.
  • 89.
  • 90. Obrigado pela Atenção! SAE de Infectologia HC UNESP Botucatu Faculdade de Medicina UNESP